康達新材(002669.SZ):擬以0元對價受讓順璟投資40%的股權
格隆匯 6 月 15日丨康達新材(002669.SZ)公佈,為通過專業化管理和市場化運作,提高投資效率,聚集新材料及軍工科技產業優質資源,發掘優質項目,藉助專業投資機構的專業投資能力和風險控制體系,公司擬與北京君曜遠方投資有限公司(“北京君曜”)、上海楚鳴管理諮詢合夥企業(有限合夥)(“上海楚鳴”)以0元對價共同收購自然人李昕磊及北京冀唐管理諮詢中心(有限合夥)(“北京冀唐”)持有的順璟投資(北京)有限公司(“順璟投資”)的股權。
順璟投資的注冊資本為人民幣3000萬元,其中公司擬以0元對價受讓李昕磊及北京冀唐分別持有的順璟投資註冊資本人民幣200萬元、1000萬元,即順璟投資40%的股權。順璟投資未來主要投資方向為新材料及軍工科技等相關領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.